CA2730079A1 - Processes for the preparation of crystalline forms of sunitinib malate - Google Patents

Processes for the preparation of crystalline forms of sunitinib malate Download PDF

Info

Publication number
CA2730079A1
CA2730079A1 CA2730079A CA2730079A CA2730079A1 CA 2730079 A1 CA2730079 A1 CA 2730079A1 CA 2730079 A CA2730079 A CA 2730079A CA 2730079 A CA2730079 A CA 2730079A CA 2730079 A1 CA2730079 A1 CA 2730079A1
Authority
CA
Canada
Prior art keywords
sunitinib
malic acid
dissolved
malate form
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2730079A
Other languages
English (en)
French (fr)
Inventor
Abhay Gaitonde
Vinayak Gore
Bharati Choudhari
Mahesh Hublikar
Prakash Bansode
Sunanda Phadtare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Original Assignee
Generics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd filed Critical Generics UK Ltd
Publication of CA2730079A1 publication Critical patent/CA2730079A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2730079A 2008-07-10 2009-07-09 Processes for the preparation of crystalline forms of sunitinib malate Abandoned CA2730079A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1193/KOL/2008 2008-07-10
IN1193KO2008 2008-07-10
PCT/GB2009/050818 WO2010004339A1 (en) 2008-07-10 2009-07-09 Processes for the preparation of crystalline forms of sunitinib malate

Publications (1)

Publication Number Publication Date
CA2730079A1 true CA2730079A1 (en) 2010-01-14

Family

ID=41100787

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2730079A Abandoned CA2730079A1 (en) 2008-07-10 2009-07-09 Processes for the preparation of crystalline forms of sunitinib malate

Country Status (7)

Country Link
US (1) US20110257237A1 (https=)
EP (1) EP2297138A1 (https=)
JP (1) JP2011527330A (https=)
CN (1) CN102203085A (https=)
AU (1) AU2009269768A1 (https=)
CA (1) CA2730079A1 (https=)
WO (1) WO2010004339A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102197035A (zh) * 2008-08-25 2011-09-21 基因里克斯(英国)有限公司 舒尼替尼的结晶形式及其制备方法
EP2499133A2 (en) * 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
WO2011092664A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
ES2709110T3 (es) * 2012-03-23 2019-04-15 Laurus Labs Ltd Un proceso mejorado para la preparación de sunitinib y sus sales de adición de ácido
CA2838587A1 (en) * 2013-10-18 2015-04-18 Hari Babu Matta Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN105085490A (zh) * 2014-05-09 2015-11-25 上海科胜药物研发有限公司 新的舒尼替尼苹果酸盐晶型及其制备方法
CN115057814A (zh) * 2021-12-07 2022-09-16 山东新时代药业有限公司 一种米力农苹果酸盐晶体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1255752T1 (sl) * 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
GEP20063777B (en) 2001-08-15 2006-03-27 Upjohn Co Crystals Including Malic Acid Salt of N-[2-(Diethylamino) Ethyl]-5-[(5-Fluoro-2-Oxo-3h-Indole-3-Ylidene) Methyl]-2, 4-Dimethyl-1h-Pyrrole-3-Carboxamide, Processes for Its Preparation and Compositions Thereof
CN1758914A (zh) * 2003-02-24 2006-04-12 苏根公司 用吲哚啉酮化合物治疗过度骨质溶解
US20040209937A1 (en) * 2003-02-24 2004-10-21 Sugen, Inc. Treatment of excessive osteolysis with indolinone compounds
EP2220071A2 (en) * 2007-11-21 2010-08-25 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof

Also Published As

Publication number Publication date
EP2297138A1 (en) 2011-03-23
US20110257237A1 (en) 2011-10-20
CN102203085A (zh) 2011-09-28
AU2009269768A1 (en) 2010-01-14
JP2011527330A (ja) 2011-10-27
WO2010004339A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
CA2730079A1 (en) Processes for the preparation of crystalline forms of sunitinib malate
JP2011512396A (ja) 新規な多形およびその調製方法
JP5916752B2 (ja) ５−クロロ−ｎ２−（２−イソプロポキシ−５−メチル−４−ピペリジン−４−イル−フェニル）−ｎ４［２−（プロパン−２−スルホニル）−フェニル］−ピリミジン−２，４−ジアミンの結晶形
CN105153122B (zh) [(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用
CN102070618A (zh) 一种化合物及其晶体
US20120029046A1 (en) Crystalline form of sunitinib and processes for its preparation
WO2014194795A1 (zh) 吲哚酮化合物或其衍生物及其用途
WO1996030367A1 (en) Piperidine derivatives
CN107709304B (zh) 苯基氨基嘧啶化合物或其盐的多晶型物
WO2009156128A1 (en) Pharmaceutical composition comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1 h-pyrrole-3-carboxamide
US20110263670A1 (en) Novel polymorphs of sunitinib and processes for their preparation
JP2011526615A (ja) ３−ピロール置換２−インドリノン誘導体の調製
JP2022507558A (ja) チエノピリドン誘導体のカリウム塩一水和物及びその調製方法
JP6072908B2 (ja) 重水素化ω―ジメチル尿素又はその塩の多形物
WO2006082598A2 (en) Novel crystalline forms of rizatriptan benzoate
CN104230848B (zh) N‑取代苯磺酰基吩噻嗪类化合物化合物及其制备方法和用途
KR20240146734A (ko) 피마살탄의 신규 염 및 이의 제조방법
CN118666843A (zh) 喹诺里西啶类组蛋白去乙酰化酶抑制剂及其制备方法与应用
WO2022194160A1 (zh) 非索替尼固体形式及其制备方法
SPECIFICATION CRYSTALLINE FORMS OF MIRABEGRON AND PROCESS FOR THEIR PREPARATION
JP2004035484A (ja) シクロヘキサンジアミン誘導体

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131219